Abstracts tagged "rheumatic disease and vasculitis"

Abstract Number: 2109 • 2017 ACR/ARHP Annual Meeting
Hyperferritinemic Syndrome in a General Hospital
Ignacio Javier Gandino¹, Florencia Pierini², Jose Maximiliano Martinez P³, Santiago Ruta², Marina Scolnik² and Enrique R Soriano⁴, ¹Reumatologia, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology, Internal Medicine Service, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ⁴Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Hyperferritinemia is associated with inflammatory conditions, such as rheumatologic diseases. Objectives: To determine which diseases are associated with hyperferritinemia in a tertiary hospital; to…
Abstract Number: 371 • 2013 ACR/ARHP Annual Meeting
Inflammatory Cell Infiltrates In The Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study
Jacqueline Kirsti Andersen¹, Ingvild Oma², Ingjerd Lien Kveldstad², Knut Mikkelsen³, Terje Veel⁴, Sven M. Almdahl⁵, Matthew H. Liang⁶, Øystein T. Førre⁷, Morten Fagerland⁸ and Ivana Hollan⁹, ¹Gjøvik University College, Gjøvik, Norway, ²Innlandet Hospital Trust, Lillehammer, Norway, ³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Feiringklinikken, Feiring, Norway, ⁵Cardiothoracic surgery, University Hospital of North Norway, Tromsø, Norway, ⁶Harvard Medical School, Boston, MA, ⁷Oslo University Hospital, Oslo, Norway, ⁸Department of Biostatistics, Oslo University Hospital, Oslo, Norway, ⁹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: Systemic rheumatic diseases (SRDs) are associated with increased cardiovascular (CV) morbidity due to accelerated atherosclerosis. However, SRDs are associated also with cardiac vasculitis that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].